This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: 108/4/445    most recent 01.CIR.0000080896.52003.DFv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Van Driest, S. L. Articles by Ackerman, M. J. Search for Related Content PubMed PubMed Citation Articles by Van Driest, S. L. Articles by Ackerman, M. J. Related Collections Clinical genetics Genomics Hypertrophy Myocardial cardiomyopathy disease Genetics of cardiovascular disease

(Circulation. 2003;108:445.)
© 2003 American Heart Association, Inc.

Clinical Investigation and Reports

Prevalence and Spectrum of Thin Filament Mutations in an Outpatient Referral Population With Hypertrophic Cardiomyopathy

Sara L. Van Driest, BA; Erik G. Ellsworth, BS; Steve R. Ommen, MD; A. Jamil Tajik, MD; Bernard J. Gersh, MB, ChB, DPhil; Michael J. Ackerman, MD, PhD

From the Department of Molecular Pharmacology and Experimental Therapeutics (S.L.V.D., M.J.A.), Mayo Medical School (E.G.E.), Department of Internal Medicine/Division of Cardiovascular Diseases (S.R.O., A.J.T., B.J.G., M.J.A.), Department of Pediatric and Adolescent Medicine/Division of Pediatric Cardiology (A.J.T., M.J.A.), Mayo Clinic, Rochester, Minn.

Correspondence to Michael J. Ackerman, MD, PhD, Sudden Death Genomics Laboratory, Guggenheim 501, Mayo Clinic, Rochester, MN 55905. E-mail ackerman.michael{at}mayo.edu

Received February 26, 2003; revision received April 29, 2003; accepted May 5, 2003.

	Abstract

Top Abstract Introduction Methods Results Discussion Conclusions Note Added in Proof References

 
Background— Thin filament mutations are reported to cause 20% of cases of hypertrophic cardiomyopathy (HCM), and they have been associated with specific phenotypes. However, the frequency of these mutations and their associated phenotype(s) from a large tertiary referral center population are unknown.

Methods and Results— DNA was obtained from 389 unrelated patients with HCM. A mutational analysis of all protein coding exons of cardiac troponin T, cardiac troponin I, -tropomyosin, and cardiac actin was performed using polymerase chain reaction, denaturing high-performance liquid chromatography, and DNA sequencing. The clinical data were extracted from patient records and maintained independent of the patient genotype. Overall, only 18 patients (4.6%) harbored isolated thin filament mutations: 8 had troponin T mutations, 6 had troponin I mutations, 3 had -tropomyosin mutations, and 1 had an actin mutation. Of the 12 unique missense mutations identified, 9 (75%) were novel mutations. As a group, patients with thin filament mutations were not significantly different from the rest of the cohort in age at diagnosis, left ventricular wall thickness, left ventricular outflow tract obstruction, or family history of HCM or sudden cardiac death.

Conclusions— Mutations in genes encoding thin filament proteins are less prevalent in HCM than previously estimated. Patients with mutations in troponin T, troponin I, -tropomyosin, and actin do not invariably present with any distinct clinical feature, thus limiting the utility of gene status for risk stratification or of clinical phenotype in guiding individual genetic screening at this time.

Key Words: hypertrophy • cardiomyopathy • genetics • death, sudden

	Introduction

Top Abstract Introduction Methods Results Discussion Conclusions Note Added in Proof References

 
Once thought to be a rare and deadly disease, it is now known that hypertrophic cardiomyopathy (HCM) is relatively common (prevalence, 0.2%) and leads to diverse clinical phenotypes.^1,2 Patient outcomes range from an asymptomatic course with normal longevity to chronic progressive heart failure or unexpected sudden cardiac death (SCD). HCM remains the leading cause of cardiac death in young people.³ The first genetic cause for HCM was defined in 1990 as a mutation in the gene encoding ß-myosin heavy chain (MYH7).⁴ Since that time, >150 different mutations have been defined in 10 different sarcomeric genes.^3,5,6

Previous reports estimated that mutations in these sarcomeric genes account for 80% of all cases of HCM.^7–9 Mutations in the thick filament (ß-myosin heavy chain and the regulatory and essential light chains) and myosin binding protein-C are estimated to cause 50% of HCM. Thin filament mutations are estimated to cause 10 to 30% of HCM. Cardiac troponin T (TNNT2) mutations have been cited to cause up to 20% of HCM,^10,11 cardiac troponin I (TNNI3) 5%,^12,13 -tropomyosin (TPM1) mutations 5%,^11,14,15 and cardiac actin (ACTC) <5%.^16,17 Mutations in the thin filament genes have been associated with specific clinical phenotypes.^{12–15,18–20}

These estimated frequencies and phenotypic associations were based on the data from early linkage studies of small, selected cohorts, usually from expansive families with high penetrance and disease expressivity.^7–9 However, these patients may not be representative of the outpatient population, which represents the majority of patients with HCM in a tertiary referral center. These estimates of mutation frequency may also be subject to publication bias, because small cohorts with negative genetic screening results may not be reported. Therefore, it was our aim to determine the frequency of thin filament HCM present in a large cohort of unrelated HCM patients seen at a tertiary referral center through a comprehensive mutational analysis of the 4 thin filament genes implicated in the pathogenesis of HCM. We also sought to determine the phenotypic correlates associated with HCM due to perturbations in the cardiac thin filament.

	Methods

Top Abstract Introduction Methods Results Discussion Conclusions Note Added in Proof References

 
Clinical Characterization of Unrelated HCM Cases
During a 4.5-year period between April 1997 and December 2001, 434 patients were evaluated at the Mayo Clinic’s HCM Clinic in Rochester, Minnesota. With standard clinical assessment of family history, relatedness was excluded through three degrees (ie, first degree, parent or sibling; second degree, grandparent, aunt, or uncle; third degree, great-grandparent, cousin, etc). Accordingly, this assessment led to the exclusion of 45 relatives. When 2 relatives were identified, the patient who was evaluated at this institution first was included for analysis. This study was therefore confined to 389 unrelated patients (age, 41.3±19 years; 215 men). Each of these subjects met the clinical diagnostic criteria for HCM of a left ventricular wall thickness (LVWT) >13 mm in the absence of another confounding diagnosis. A blood sample was provided for molecular genetic testing after obtaining informed, written consent in accordance with study protocols approved by the Mayo Foundation Institutional Review Board.

Mutational Analysis
Purgene DNA extraction kits (Gentra, Inc) were used to extract patient genomic DNA from peripheral blood lymphocytes. Previously published intron/exon-based primers or novel primers were used to amplify the protein-coding exons of the 4 thin filament genes (TNNT2, TNNI3, TPM1, and ACTC) from genomic DNA from each of the 389 patients by polymerase chain reaction.¹⁴ Sequence variations were detected by denaturing high performance liquid chromatography (DHPLC) using the Transgenomic WAVE system, as previously described.²¹ Primer sequences and conditions for polymerase chain reaction and DHPLC are indicated in the Data Supplement Table. Abnormal DHPLC elution profiles were further characterized by automated dye terminator cycle-sequencing using an ABI Prism 377 (Applied Biosystems).²² When novel sequence variations were identified, DNA samples from 100 healthy white and 100 healthy black individuals (Coriell Cell Repositories) were analyzed to exclude the variant’s presence as a common polymorphism in unaffected individuals.

Statistical Analysis
Differences between continuous variables were assessed using unpaired t tests. Nominal variables were analyzed using contingency tables or z-tests, where appropriate. A probability value <0.05 was considered statistically significant.

	Results

Top Abstract Introduction Methods Results Discussion Conclusions Note Added in Proof References

 
Characterization of the HCM Cohort
Table 1 summarizes the demographics for the 389 unrelated individuals with HCM. The mean age at diagnosis was 41.3±19 years. At presentation to Mayo Clinic, 216 patients (55.5%) had cardiac symptoms. Approximately one-third (30.8%) had a family history of HCM involving a first-degree relative (parent, sibling, or offspring), and 14.4% had a family history of unexplained SCD involving a first-degree relative. The mean maximal LVWT was 21.5±7 mm. Of the 389 patients, 161 patients underwent a surgical myectomy (41.4%), and 60 patients have an implanted cardioverter defibrillator (15.4%).

View this table: [in this window] [in a new window]   TABLE 1. Clinical Characteristics of HCM Patient Cohort

Prevalence and Phenotype of Thin Filament HCM
In this cohort, only 18 of 389 unrelated individuals (4.6%) harbored isolated thin filament mutations. The mutation identified and clinical profile for each of the mutation-positive patients are summarized in Table 2. There was no statistically significant difference between the 18 thin filament HCM patients and the remainder of the cohort in age at diagnosis, LVWT, maximum left ventricular outflow tract gradient, family history of HCM or SCD, pattern of hypertrophy, or previous invasive therapies (eg, myectomy; Table 1).

View this table: [in this window] [in a new window]   TABLE 2. Clinical Profiles of HCM Patients With Thin Filament Mutations

Spectrum of Thin Filament Mutations
Figure 1 depicts the genes encoding the 4 thin filament proteins and the locations of the mutations identified. Overall, 12 unique missense mutations were identified, including 9 novel mutations. Each of these 9 novel mutations was absent in 400 reference alleles.

View larger version (20K): [in this window] [in a new window]   Figure 1. Thin filament genes and HCM-causing mutations. Boxes indicate exons; lines, introns. Previously published mutations are labeled below each gene, and mutations found in the present analysis are indicated above each gene. * indicates a novel mutation found in the present study.

Troponin T
Five missense mutations in TNNT2 were identified in 8 patients with HCM (2.1%). Two were novel mutations: D86A (1 patient) and R286H (2 patients). The remaining 3 mutations, R92W (1 patient), R278P (1 patient) and R278C (3 patients), have previously been reported in association with HCM. In these 8 patients, HCM was diagnosed at 37.2±18 years. This subset of patients had a mean LVWT of 23.4±6 (range, 15 to 32 mm), which was not statistically different from the remainder of the cohort. In the present study, no patient with a TNNT2 mutation had SCD in a first-degree relative.

Troponin I
Three novel TNNI3 missense mutations were identified in 6 patients: R141Q (1 patient), R162Q (2 patients), and S166F (3 patients). Five of the 6 patients had obstructive HCM with a mean resting peak gradient of 88±21 mm Hg. All 5 required a septal myectomy. Of the 6 patients with TNNI3 mutations, 3 were diagnosed before 30 years of age. None of the 34 patients with apical hypertrophy in our study had a TNNI3 mutation, and the age at onset was not statistically different from the cohort as a whole (44.3±24 versus 41.3±19 years).

-Tropomyosin
Three novel mutations were identified in TPM1 (0.8%), each in a single patient (I172T, L185R, and M281T). Two of these 3 individuals had a family history of HCM and SCD in a first-degree relative. One previously reported patient (index case 16) was asymptomatic at 42 years, but 2 of his 3 mutation-positive children died of SCD due to HCM before 9 years of age.²³

Actin
One actin mutation was identified (A232V) in a 48-year-old female patient. She was diagnosed at 41 years when she presented with angina and dyspnea. She had a first-degree relative with HCM and a 40-year-old sibling who died from SCD.

	Discussion

Top Abstract Introduction Methods Results Discussion Conclusions Note Added in Proof References

 
Cohort Analysis
The 389 patients evaluated in this study represent unrelated patients seen at a tertiary referral center with known expertise in the surgical management of HCM. When compared with a cohort of 744 patients seen in 3 regional centers, the age at initial evaluation and LVWT are not significantly different.²⁴ However, our cohort has a larger representation of patients with outflow tract obstruction (53% versus 22% in regional centers) and myectomy (41% versus 5% in regional centers).²⁴ Therefore, our cohort is comparable in age and degree of hypertrophy to the population of patients with HCM, but may be over-represented with patients having significant outflow tract gradients secondary to surgical referral bias.

Frequency of Thin Filament Mutations in a Tertiary HCM Referral Center
In the present study, we found that <5% of unrelated HCM patients had thin filament mutations. It has been suggested that as many as 20% of HCM cases may be due to mutations in the TNNT2, TNNI3, TPM1, or ACTC genes.^7–9 However, these estimates have been drawn from the pioneering sentinel studies that established HCM as a molecular disease of the sarcomere.^11,12,14 By necessity, these linkage studies involved selected, multigenerational pedigrees having a high penetrance of the underlying HCM genotype.

Studies of mutation frequency in large, unselected cohorts are lacking. Analysis of a small cohort of Finnish patients for TNNI3 (37 unrelated patients) and ACTC (40 unrelated patients) revealed no causative mutations in either of these genes.^25,26 Our analysis of a large cohort of unrelated patients seen in a tertiary HCM referral center confirms the relative rarity of thin filament HCM.

Phenotype of Patients With Thin Filament HCM
Several genotype-phenotype correlations have been suggested for genes of the thin filament.⁷ TNNT2-HCM has been associated with minimal hypertrophy and a high risk for SCD.¹⁸ In the present study, the 8 TNNT2-positive individuals did not have significantly less hypertrophy than the rest of the cohort, and none of the 8 had a family history of SCD.

TNNI3 mutations have been associated with apical HCM and elderly onset of disease.^12,13 Of the 6 patients identified with TNNI3 defects, none had apical hypertrophy, and 3 were diagnosed before 30 years of age. HCM due to perturbations of TPM1 have been associated with variable outcomes.^14,15,19,20 In our cohort, 2 of the 3 individuals with TPM1-HCM had a family history of SCD. Finally, several reported cases of ACTC-HCM have presented with apical hypertrophy.¹⁷ The one patient with the ACTC mutation in this cohort did not have apical hypertrophy.

The results of the present study warrant caution for application of prior genotype-phenotype associations for individual HCM patients based solely on the HCM-causing gene mutation. This is consistent with our previous studies, which demonstrated that the presence or absence of specific HCM mutations previously annotated as "malignant" or "benign" should not be used for prognosis or risk stratification.^27,28

From our previous studies, it also seems that the phenotype may not be a reliable predictor of the specific causative mutation.^27,28 In the subgroup of individuals harboring thin filament defects (n=18), no statistical difference was evident when compared with the rest of the cohort. Our findings suggest that individuals with thin filament mutations had a similar degree of hypertrophy, age at presentation, and incidence of a family history of SCD as those without such mutations. Because of the rarity of thin filament mutations, however, definitive phenotypic correlations will be difficult to establish until mutation identification becomes more technically feasible for additional large cohorts. Presently, it cannot be concluded on the basis of this large cohort of unrelated HCM patients whether or not thin filament HCM is "thinner" than HCM mediated by thick filament mutations, as has been suggested previously.²⁹

Putative Functional Consequence of HCM-Causing Mutations in This Cohort
Figure 2 illustrates the normal structural relationships of the thin filament. HCM-causing mutations in the thin filament most often lie in domains lying at the interface of 2 proteins and lead to increased calcium sensitivity.^30–32 The mutations reported herein also reside within established protein-protein binding domains. In TNNT2, the D86A and R92W mutations lie in the TPM1-binding region. R286H-TNNT2 and R278C/P-TNNT2 lie in the TPM1 and troponin-binding domain. The TNNI3 mutations identified occur in functionally significant domains. R141Q-TNNI3 lies within the "minimum inhibitory sequence" (residues 137 to 148), and both R162Q and S166F reside within the troponin C binding site.³³ In TPM1, 2 of the novel mutations reported here (I172T and M281T) affect residues at the TPM1 dimer interface. However, the L185R-TPM1 mutation alters a residue on the outside surface of the fiber within the troponin-binding domain. The severe phenotype seen in the family with this mutation may be due to functionally distinct effects on troponin binding rather than filament stability.²³ Finally, the A232V-ACTC mutation lies within the TPM1-binding domain.

View larger version (86K): [in this window] [in a new window]   Figure 2. Structural relationships of proteins comprising the thin filament of the cardiac sarcomere. Adapted from reference 5 (Spirito P, Seidman CE, McKenna WJ, et al. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336:775–785).

Study Limitations
It is possible that our mutational analysis by DHPLC failed to detect mutations present in this cohort, which would account, in part, for the apparent low yield of thin filament HCM. However, the sensitivity of DHPLC for mutation detection has been established as >95%.³⁴ It is well known that the sensitivity of DHPLC is context-dependent. Therefore, for this study, DHPLC conditions for each amplicon were individually optimized. Of the 37 amplicons analyzed, 3 required >1 melting temperature to ensure comprehensive coverage of the amplicon by temperature-modulated heteroduplex analysis. Two GC-clamped primers were necessary. Our own internal quality control studies of our optimization methods using direct sequencing as the gold standard indicate a sensitivity of mutation detection by DHPLC of 100% (data not shown).

As previously noted, analysis of the clinical presentation of our cohort indicated an increased percentage of patients with significant outflow tract obstructions and a greater number of patients undergoing surgical myectomy for symptom relief. Otherwise, our cohort was similar to unselected regional center patients. Although it is important to recognize this selection bias, studies of selected cohorts have in the past provided the foundation for understanding HCM genetics. Similarly, careful analysis of our cohort provides the opportunity for a unique perspective and new insights for this heterogeneous disease.

Although we excluded individuals from the cohort who were clinically identified as first-, second-, or third-degree relatives, we did not use molecular haplotype analysis to rule out the possibility of relatedness in a more distant manner. Therefore, our 5% frequency of thin filament HCM could be an underestimate if there is a founder effect (ie, distant common ancestor) for several individuals in the cohort who were negative for thin filament mutations. However, if the individuals identified with identical thin filament mutations share a common ancestor, then the stated 5% frequency would overestimate the true prevalence of thin filament HCM.

Previous studies determined genotype-disease severity correlations based on survival curves for mutation-positive family members. Herein lies a major difference in the perspective brought by the present study. Our cohort included 389 unrelated individuals, and we searched for genotype-phenotype correlation in these individuals, who do not necessarily share genetic and environmental modifiers. This study design, although it precludes analyses such as Kaplan-Meier survival curves or mutation cosegregation within families, reveals that these modifiers may play a major role in the presentation and course of this disease, because correlations previously defined using related individuals were not found in this unrelated cohort. Although segregation data would provide additional evidence to substantiate the ascribed pathogenic status of the 9 novel mutations, none of these mutations have been identified in the healthy population, as based on previous studies, the National Center for Biotechnology Information database, and our own analysis of 400 reference alleles. In addition, the anticipated functional consequence of these mutations, based on their position in the protein product, is consistent with firmly established pathogenic mechanisms for HCM.

Finally, because of the rarity of mutations in the thin filament found in our study, it is difficult to achieve statistical significance for genotype-phenotype correlation in unrelated family members. Thus, despite evaluating nearly 400 unrelated cases of HCM, we are unable to statistically confirm or refute previous genotype-phenotype correlations implicated for thin filament HCM. As the technology for high-throughput genetic screening advances, the potential to elucidate meaningful associations between genetic cause and clinical presentation may become a reality.

	Conclusions

Top Abstract Introduction Methods Results Discussion Conclusions Note Added in Proof References

 
In this cohort of 389 unrelated HCM patients from an outpatient tertiary referral center, thin filament mutations were uncommon (<5%) and were not distinguishable from non–thin filament causes of HCM by patient age at presentation, clinical course, family history, or anatomic type. Further study of genetic and environmental modifiers may reveal determinants mitigating the profound phenotypic variability seen in HCM.

	Note Added in Proof

Top Abstract Introduction Methods Results Discussion Conclusions Note Added in Proof References

 
While this manuscript was in press, Richard and colleagues³⁵ reported the distribution of HCM-causing mutations among 197 unrelated index cases and identified 16 patients (8%) with thin filament HCM.

	Acknowledgments

 
This study was supported by a Mayo Foundation Clinician Research award to Dr Ackerman. We are indebted to the patients seen in the Hypertrophic Cardiomyopathy Clinic at Mayo Clinic, Rochester, for their willingness to participate in this study and to Douglas Kocer, RN, nurse coordinator for the HCM Clinic. We also thank Rick A. Nishimura, Director of the HCM Clinic, for his advice, guidance, and support of the translational HCM genomics program and careful reading of this manuscript.

	Footnotes

 
The online Table is available in the online-only Data Supplement at http://www.circulationaha.org.

	References

Top Abstract Introduction Methods Results Discussion Conclusions Note Added in Proof References

 
1. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study: Coronary Artery Risk Development in (Young) Adults. Circulation. 1995; 92: 785–789.[Abstract/Free Full Text]

2. Maron BJ, Bonow RO, Cannon RO, et al. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med. 1987; 316: 780–789.[Medline] [Order article via Infotrieve]

3. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002; 287: 1308–1320.[Abstract/Free Full Text]

4. Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell. 1990; 62: 999–1006.[CrossRef][Medline] [Order article via Infotrieve]

5. Spirito P, Seidman CE, McKenna WJ, et al. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997; 336: 775–785.[Free Full Text]

6. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell. 2001; 104: 557–567.[CrossRef][Medline] [Order article via Infotrieve]

7. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2001; 33: 655–670.[CrossRef][Medline] [Order article via Infotrieve]

8. Burch M, Blair E. The inheritance of hypertrophic cardiomyopathy. Pediatr Cardiol. 1999; 20: 313–316.[CrossRef][Medline] [Order article via Infotrieve]

9. Roberts R, Sigwart U. New concepts in hypertrophic cardiomyopathies, part I. Circulation. 2001; 104: 2113–2116.[Free Full Text]

10. Varnava AM, Elliott PM, Baboonian C, et al. Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation. 2001; 104: 1380–1384.[Abstract/Free Full Text]

11. Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med. 1995; 332: 1058–1064.[Abstract/Free Full Text]

12. Kimura A, Harada H, Park JE, et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet. 1997; 16: 379–382.[CrossRef][Medline] [Order article via Infotrieve]

13. Niimura H, Patton KK, McKenna WJ, et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation. 2002; 105: 446–451.[Abstract/Free Full Text]

14. Thierfelder L, Watkins H, MacRae C, et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell. 1994; 77: 701–712.[CrossRef][Medline] [Order article via Infotrieve]

15. Karibe A, Tobacman LS, Strand J, et al. Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal myosin cycling, and poor prognosis. Circulation. 2001; 103: 65–71.[Abstract/Free Full Text]

16. Mogensen J, Klausen IC, Pedersen AK, et al. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest. 1999; 103: R39–R43.[Medline] [Order article via Infotrieve]

17. Olson TM, Doan TP, Kishimoto NY, et al. Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2000; 32: 1687–1694.[CrossRef][Medline] [Order article via Infotrieve]

18. Moolman JC, Corfield VA, Posen B, et al. Sudden death due to troponin T mutations. J Am Coll Cardiol. 1997; 29: 549–555.[Abstract]

19. Yamauchi-Takihara K, Nakajima-Taniguchi C, Matsui H, et al. Clinical implications of hypertrophic cardiomyopathy associated with mutations in the alpha-tropomyosin gene. Heart. 1996; 76: 63–65.[Abstract/Free Full Text]

20. Regitz-Zagrosek V, Erdmann J, Wellnhofer E, et al. Novel mutation in the alpha-tropomyosin gene and transition from hypertrophic to hypocontractile dilated cardiomyopathy. Circulation. 2000; 102: 112–116.

21. Underhill PA, Jin L, Lin AA, et al. Detection of numerous Y chromosome biallelic polymorphisms by denaturing high-performance liquid chromatography. Genome Res. 1997; 7: 996–1005.[Abstract/Free Full Text]

22. Ackerman MJ, Schroeder JJ, Berry R, et al. A novel mutation in KVLQT1 is the molecular basis of inherited long QT syndrome in a near-drowning patient’s family. Pediatr Res. 1998; 44: 148–153.[Medline] [Order article via Infotrieve]

23. Van Driest SL, Will ML, Atkins DL, et al. A novel TPM1 mutation in a family with hypertrophic cardiomyopathy and sudden cardiac death in childhood. Am J Cardiol. 2002; 90: 1123–1127.[CrossRef][Medline] [Order article via Infotrieve]

24. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000; 102: 858–864.[Abstract/Free Full Text]

25. Jaaskelainen P, Miettinen R, Silvennoinen K, et al. The cardiac troponin I gene is not associated with hypertrophic cardiomyopathy in patients from eastern Finland. J Mol Cell Cardiol. 1999; 31: 2031–2036.[CrossRef][Medline] [Order article via Infotrieve]

26. Karkkainen S, Peuhkurinen K, Jaaskelainen P, et al. No variants in the cardiac actin gene in Finnish patients with dilated or hypertrophic cardiomyopathy. Am Heart J. 2002; 143: E6.[Medline] [Order article via Infotrieve]

27. Van Driest SV, Ackerman MJ, Ommen SR, et al. Prevalence and severity of "benign" mutations in the beta myosin heavy chain, cardiac troponin-T, and alpha tropomyosin genes in hypertrophic cardiomyopathy. Circulation. 2002; 106: 3085–3090.[Abstract/Free Full Text]

28. Ackerman MJ, Van Driest SV, Ommen SR, et al. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T gene in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. J Am Coll Cardiol. 2002; 39: 2042–2048.[Abstract/Free Full Text]

29. Marian AJ, Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation. 1995; 92: 1336–1347.[Free Full Text]

30. Hernandez OM, Housmans PR, Potter JD. Pathophysiology of cardiac muscle contraction and relaxation as a result of alterations in thin filament regulation. J Appl Physiol. 2001; 90: 1125–1136.[Abstract/Free Full Text]

31. Michele DL, Metzger JM. Physiological consequences of tropomyosin mutations associated with cardiac and skeletal myopathies. J Mol Med. 2000; 78: 543–553.[CrossRef][Medline] [Order article via Infotrieve]

32. Szczesna D, Zhang R, Zhao J, et al. Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy. J Biol Chem. 2000; 275: 624–630.[Abstract/Free Full Text]

33. Tripet B, Van Eyk JE, Hodges RS. Mapping of a second actin-tropomyosin and a second troponin C binding site within the C terminus of troponin I, and their importance in the Ca2+-dependent regulation of muscle contraction. J Mol Biol. 1997; 271: 728–750.[CrossRef][Medline] [Order article via Infotrieve]

34. Xiao W, Oefner P. Denaturing high-performance liquid chromatography: a review. Hum Mutat. 2001; 17: 439–474.[CrossRef][Medline] [Order article via Infotrieve]

35. Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003; 107: 2227–2232.[Abstract/Free Full Text]

This article has been cited by other articles:

				M. Michels, O. I.I. Soliman, J. Phefferkorn, Y. M. Hoedemaekers, M. J. Kofflard, D. Dooijes, D. Majoor-Krakauer, and F. J. Ten Cate Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers Eur. Heart J., November 1, 2009; 30(21): 2593 - 2598. [Abstract] [Full Text] [PDF]

				J. R. Pinto, M. S. Parvatiyar, M. A. Jones, J. Liang, M. J. Ackerman, and J. D. Potter A Functional and Structural Study of Troponin C Mutations Related to Hypertrophic Cardiomyopathy J. Biol. Chem., July 10, 2009; 284(28): 19090 - 19100. [Abstract] [Full Text] [PDF]

				M. Penicka, P. Gregor, R. Kerekes, D. Marek, K. Curila, J. Krupicka, and for the Candesartan use in Hypertrophic And Non-ob The Effects of Candesartan on Left Ventricular Hypertrophy and Function in Nonobstructive Hypertrophic Cardiomyopathy: A Pilot, Randomized Study J. Mol. Diagn., January 1, 2009; 11(1): 35 - 41. [Abstract] [Full Text] [PDF]

				Y. Wen, J. R. Pinto, A. V. Gomes, Y. Xu, Y. Wang, Y. Wang, J. D. Potter, and W. G. L. Kerrick Functional Consequences of the Human Cardiac Troponin I Hypertrophic Cardiomyopathy Mutation R145G in Transgenic Mice J. Biol. Chem., July 18, 2008; 283(29): 20484 - 20494. [Abstract] [Full Text] [PDF]

				I. Olivotto, F. Girolami, M. J. Ackerman, S. Nistri, J. M. Bos, E. Zachara, S. R. Ommen, J. L. Theis, R. A. Vaubel, F. Re, et al. Myofilament Protein Gene Mutation Screening and Outcome of Patients With Hypertrophic Cardiomyopathy Mayo Clin. Proc., June 1, 2008; 83(6): 630 - 638. [Abstract] [Full Text] [PDF]

				H. Matsson, J. Eason, C. S. Bookwalter, J. Klar, P. Gustavsson, J. Sunnegardh, H. Enell, A. Jonzon, M. Vikkula, I. Gutierrez, et al. Alpha-cardiac actin mutations produce atrial septal defects Hum. Mol. Genet., January 15, 2008; 17(2): 256 - 265. [Abstract] [Full Text] [PDF]

				M. Medin, M. Hermida-Prieto, L. Monserrat, R. Laredo, J. C. Rodriguez-Rey, X. Fernandez, and A. Castro-Beiras Mutational screening of phospholamban gene in hypertrophic and idiopathic dilated cardiomyopathy and functional study of the PLN -42 C>G mutation Eur J Heart Fail, January 1, 2007; 9(1): 37 - 43. [Abstract] [Full Text] [PDF]

				S. G. Sirenko, J. D. Potter, and B. C. Knollmann Differential effect of troponin T mutations on the inotropic responsiveness of mouse hearts - role of myofilament Ca2+ sensitivity increase J. Physiol., August 15, 2006; 575(1): 201 - 213. [Abstract] [Full Text] [PDF]

				C. Y. Ho and C. E. Seidman A Contemporary Approach to Hypertrophic Cardiomyopathy Circulation, June 20, 2006; 113(24): e858 - e862. [Full Text] [PDF]

				C. S. Bookwalter and K. M. Trybus Functional Consequences of a Mutation in an Expressed Human {alpha}-Cardiac Actin at a Site Implicated in Familial Hypertrophic Cardiomyopathy J. Biol. Chem., June 16, 2006; 281(24): 16777 - 16784. [Abstract] [Full Text] [PDF]

				L. Song, S. R. DePalma, M. Kharlap, A. G. Zenovich, A. Cirino, R. Mitchell, B. McDonough, B. J. Maron, C. E. Seidman, J.G. Seidman, et al. Novel Locus for an Inherited Cardiomyopathy Maps to Chromosome 7 Circulation, May 9, 2006; 113(18): 2186 - 2192. [Abstract] [Full Text] [PDF]

				J. Binder, S. R. Ommen, B. J. Gersh, S. L. Van Driest, A. J. Tajik, R. A. Nishimura, and M. J. Ackerman Echocardiography-Guided Genetic Testing in Hypertrophic Cardiomyopathy: Septal Morphological Features Predict the Presence of Myofilament Mutations Mayo Clin. Proc., April 1, 2006; 81(4): 459 - 467. [Abstract] [Full Text] [PDF]

				J. H. Brown, Z. Zhou, L. Reshetnikova, H. Robinson, R. D. Yammani, L. S. Tobacman, and C. Cohen Structure of the mid-region of tropomyosin: Bending and binding sites for actin PNAS, December 27, 2005; 102(52): 18878 - 18883. [Abstract] [Full Text] [PDF]

				O. M. Hernandez, D. Szczesna-Cordary, B. C. Knollmann, T. Miller, M. Bell, J. Zhao, S. G. Sirenko, Z. Diaz, G. Guzman, Y. Xu, et al. F110I and R278C Troponin T Mutations That Cause Familial Hypertrophic Cardiomyopathy Affect Muscle Contraction in Transgenic Mice and Reconstituted Human Cardiac Fibers J. Biol. Chem., November 4, 2005; 280(44): 37183 - 37194. [Abstract] [Full Text] [PDF]

				M. J. Perkins, S. L. Van Driest, E. G. Ellsworth, M. L. Will, B. J. Gersh, S. R. Ommen, and M. J. Ackerman Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy Eur. Heart J., November 2, 2005; 26(22): 2457 - 2462. [Abstract] [Full Text] [PDF]

				M. J. Ackerman, S. L. Van Driest, and M. Bos Are Longitudinal, Natural History Studies the Next Step in Genotype-Phenotype Translational Genomics in Hypertrophic Cardiomyopathy? J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1744 - 1746. [Full Text] [PDF]

				M. Arad, M. Penas-Lado, L. Monserrat, B. J. Maron, M. Sherrid, C. Y. Ho, S. Barr, A. Karim, T. M. Olson, M. Kamisago, et al. Gene Mutations in Apical Hypertrophic Cardiomyopathy Circulation, November 1, 2005; 112(18): 2805 - 2811. [Abstract] [Full Text] [PDF]

				J. Mogensen and W. J. McKenna Reply J. Am. Coll. Cardiol., July 5, 2005; 46(1): 181 - 181. [Full Text] [PDF]

				S. L. Van Driest, S. R. Ommen, A. J. Tajik, B. J. Gersh, and M. J. Ackerman Yield of Genetic Testing in Hypertrophic Cardiomyopathy Mayo Clin. Proc., June 1, 2005; 80(6): 739 - 744. [Abstract] [PDF]

				S. L. Van Driest, S. R. Ommen, A. J. Tajik, B. J. Gersh, and M. J. Ackerman Sarcomeric Genotyping in Hypertrophic Cardiomyopathy Mayo Clin. Proc., April 1, 2005; 80(4): 463 - 469. [Abstract] [PDF]

				J. Mogensen, R. T. Murphy, T. Kubo, A. Bahl, J. C. Moon, I. C. Klausen, P. M. Elliott, and W. J. McKenna Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2315 - 2325. [Abstract] [Full Text] [PDF]

				C. A. MacRae and P. T. Ellinor Genetic screening and risk assessment in hypertrophic cardiomyopathy J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2326 - 2328. [Full Text] [PDF]

				J. A. Towbin and R. J. Solaro Genetics of dilated cardiomyopathy: More genes that kill J. Am. Coll. Cardiol., November 16, 2004; 44(10): 2041 - 2043. [Full Text] [PDF]

				S. L. Van Driest, V. C. Vasile, S. R. Ommen, M. L. Will, A. J. Tajik, B. J. Gersh, and M. J. Ackerman Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1903 - 1910. [Abstract] [Full Text] [PDF]

				S. L. Van Driest, M. A. Jaeger, S. R. Ommen, M. L. Will, B. J. Gersh, A. J. Tajik, and M. J. Ackerman Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy J. Am. Coll. Cardiol., August 4, 2004; 44(3): 602 - 610. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: 108/4/445    most recent 01.CIR.0000080896.52003.DFv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Van Driest, S. L. Articles by Ackerman, M. J. Search for Related Content PubMed PubMed Citation Articles by Van Driest, S. L. Articles by Ackerman, M. J. Related Collections Clinical genetics Genomics Hypertrophy Myocardial cardiomyopathy disease Genetics of cardiovascular disease